What is Sinopia Biosciences?
Sinopia Biosciences is a specialized biotechnology firm dedicated to altering the clinical trajectory of Parkinson's disease. Operating out of San Diego, California, the company focuses on the intersection of innovative research and development to create targeted solutions for patients suffering from neurodegenerative conditions. Their business model centers on the advancement of a robust therapeutic pipeline, designed to provide healthcare providers and clinical organizations with more effective tools for disease management.
The company distinguishes itself through a commitment to rigorous scientific inquiry and strategic collaboration. By engaging with both public and private stakeholders, Sinopia Biosciences seeks to bridge the gap between laboratory discovery and patient-centric care, ultimately aiming to improve long-term outcomes for those affected by Parkinson's disease.
How much funding has Sinopia Biosciences raised?
Sinopia Biosciences has raised a total of $8.2M across 4 funding rounds:
Debt
$82K
Other Financing Round
$2M
Grant
$3.3M
Stock/Share Issuance
$2.8M
Debt (2021): $82K with participation from PPP
Other Financing Round (2023): $2M led by The Michael J. Fox Foundation for Parkinson’s Research
Grant (2023): $3.3M supported by National Institute of Neurological Disorders and Stroke
Stock/Share Issuance (2026): $2.8M, investors not publicly disclosed
Key Investors in Sinopia Biosciences
National Institute of Neurological Disorders and Stroke
The National Institute of Neurological Disorders and Stroke is a U.S. government organization dedicated to advancing research and health related to brain and nervous system disorders, providing critical support for clinical trials and neurological innovation.
The Michael J. Fox Foundation for Parkinson’s Research
A leading non-profit organization focused on accelerating scientific research and drug development to find a cure for Parkinson's disease through strategic grant-making and advocacy.
PPP
Public-Private Partnership
What's next for Sinopia Biosciences?
With the successful closure of this major strategic investment, Sinopia Biosciences is poised to scale its operational capacity and accelerate its clinical development timelines. The company's roadmap likely involves expanding its research team, enhancing its laboratory infrastructure, and initiating more comprehensive clinical trials to validate its therapeutic candidates. Furthermore, the firm is expected to leverage its recent capital to pursue high-value partnerships with established healthcare organizations, which will be instrumental in navigating the regulatory landscape and facilitating the eventual commercialization of its pipeline. As the company matures, its focus will remain on maintaining the scientific integrity of its research while demonstrating the scalability of its neurological interventions to potential investors and clinical partners.
See full Sinopia Biosciences company page
